Where the Med Spa, Wellness and Telehealth Market Is Actually Headed — With the Data

The Data Behind the Headlines

Most "the industry is booming" claims in aesthetics and wellness get repeated without a source attached. The actual data — pulled from named market research reports, not a general sense that things are growing — tells a consistent story: wellness spending keeps climbing, weight-loss prescribing has become a genuine category rather than a passing trend, and telehealth has moved from pandemic-era workaround to permanent infrastructure.

None of that is abstract if you run a clinic. Each trend below has a direct, practical implication for what your menu should include and what your compliance structure needs to support — which is the point of pulling the numbers together in one place rather than reacting to whichever headline shows up first.

The Wellness Economy Is Enormous, and Still Accelerating

The Global Wellness Institute's 2025 Global Wellness Economy Monitor puts the global wellness economy at $6.8 trillion in 2024 — up 7.9% from the year before, and roughly double its size a decade earlier. The United States alone accounts for $2.1 trillion of that total, more than any other single country.

"Wellness" in that figure spans eleven sectors, from fitness to nutrition to spas, and a given clinic sits in only a slice of it. The trajectory matters regardless of exactly which slice: this is not a niche category leveling off, it is one still compounding at a rate most industries would consider remarkable at this scale.

Med Spas Are One of the Fastest-Growing Categories Inside It

Within that broader wellness economy, medical aesthetics is one of the categories growing fastest. Industry estimates put the global med spa market at roughly $50 billion, growing at close to 16% annually, with the U.S. representing the single largest national market at around $26 billion.

That growth rate is well above the wellness economy's overall 7.9% — med spas are outgrowing the broader category they sit inside of, which is a real part of why competition for the same patient base keeps intensifying rather than settling down.

GLP-1 Demand: Patients Are Already There

The clearest single data point in this space might be patient adoption itself. PwC's research on GLP-1 medications and consumer health found that over 8% of American adults already report using a GLP-1, with another 35% saying they are interested in trying one. That is not early-adopter territory — it is a meaningful, and growing, share of the general population.

The Market Growth Backs It Up

The market data lines up with what patients are reporting. Grand View Research projects the GLP-1 weight-loss drug market to grow from about $13.8 billion in 2024 to roughly $48.8 billion by 2030 — an 18.5% compound annual growth rate. A clinic without a real weight-loss prescribing program at this point is not ahead of a trend anymore; it is behind patient demand that has already arrived.

Telehealth Went From Emergency Workaround to Permanent Infrastructure

Telehealth's growth did not stop when pandemic-era flexibilities wound down — it kept compounding. MarketsandMarkets projects the U.S. telehealth market to grow from about $46 billion in 2024 to roughly $84 billion by 2030, nearly doubling in six years.

For a clinic, that growth means telehealth is not a side channel anymore — it is core infrastructure, which is exactly why per-state physician licensing keeps becoming more relevant rather than less. More of the industry's growth is happening in a channel that requires a director licensed wherever the patient actually is, not just where the clinic's office sits.

What This Actually Means for Your Clinic

• If GLP-1 or weight-loss prescribing isn't on your menu yet: patient demand has already outpaced a lot of clinics' service lines — see our breakdown of why med spas need wellness services now for what adding it correctly actually requires.
• If you're not set up for telehealth in more than one state: growth in that channel means the clinics capturing it are the ones with per-state physician coverage already built, not the ones scrambling to add it after demand shows up.
• If your menu hasn't changed in the last year: the category you compete in is growing faster than the broader wellness economy, which means standing still is a relative decline even if your own numbers look flat.
• If you're adding services to chase this growth: each one still needs its own protocol, sourcing check and, where applicable, DEA or controlled-substance consideration — growth in demand does not reduce what compliance requires, it raises the stakes of skipping it.

A Note on These Numbers

Market-size estimates in every category covered here vary meaningfully by research firm. Different reports define "the telehealth market" or "the GLP-1 market" differently, use different base years, and can arrive at figures that differ by a factor of two or more for what sounds like the same category.

The numbers cited above come from named, specific reports — the Global Wellness Institute, Grand View Research, MarketsandMarkets and PwC — so they can be checked against their original source rather than taken on faith. Read them as directional indicators of scale and trajectory, not as a single figure the entire industry has agreed on.

Where MedGrid Fits

Whichever direction this data points your clinic — adding GLP-1 prescribing, expanding telehealth into new states, or simply keeping pace with a faster-growing category — the underlying requirement is the same: a real medical director, protocols written for what you're actually adding, and sourcing that's been checked, not assumed. MedGrid builds that structure to move with the menu, rather than needing to be rebuilt every time the data changes.

Frequently Asked Questions

• Where do these numbers actually come from?: Each figure cited above comes from a named market research report or industry organization — the Global Wellness Institute, Grand View Research, MarketsandMarkets and PwC are cited specifically so the numbers can be checked against their original source rather than taken on faith.
• Why do market-size numbers vary so much between sources?: Different research firms define category boundaries differently — "the GLP-1 market," for example, can mean weight-loss-specific drugs only, or every GLP-1 receptor agonist including diabetes indications, which produces very different totals for what sounds like the same category.
• Does strong industry growth mean opening a clinic is a safe bet?: No — industry-level growth describes the category, not any individual clinic's odds. A growing market can still have plenty of businesses within it that get the structure wrong and struggle regardless of overall demand.
• How often does data like this actually change?: Meaningfully, year to year — several of the reports cited here are updated annually. Treat these figures as a snapshot as of when this was published, not a permanent baseline.

This article summarizes third-party market research for informational purposes; it is not financial, medical or legal advice, and MedGrid did not produce the underlying data. Market conditions change — verify figures against the original sources before relying on them for a business decision.